Illumina Ventures
@illuminaventure
Followers
917
Following
588
Media
322
Statuses
946
Independent, exclusively genomics- and precision medicine-focused firm investing in pioneering tools, therapeutics and diagnostics.
San Francisco, CA
Joined March 2016
Congrats to portfolio company Syntax Bio’s: 🏆 Dr. Brad Merrill, 2025 @IllinoisBiotech iCON Innovator Award recipient. Details: https://t.co/IDFNs91AqQ. 🏆 Dr. Ryan Clarke, recognized on @CrainsChicago 2025 40 Under 40. More info: https://t.co/l6BScz5d0d.
#PartnerNews
0
0
0
.@DrugDiscovNews featured four portfolio company leaders' expertise on how multi-omics is transforming and redefining the ways biology is measured, modeled & controlled—making #DrugDiscovery more mechanism-aware and precision-driven. 👉Full article: https://t.co/G8EkzVqgO3
1
0
0
Founding Partner Nick Naclerio, PhD, will join LinkBridge Investors’ Global Investors Annual Meeting on 11/18 in Newport Beach, CA with leading VCs and investors for panels and 1:1 discussions on emerging market trends and strategies. Details: https://t.co/D1Q8WjLp8W
0
0
0
Congrats to Hepta on unveiling the first multi-omic atlas of #MASH. This breakthrough connects liver pathway biology with cfDNA methylation signatures in blood, creating a non-invasive molecular window into liver health. 📢 https://t.co/cawd7hYyry
#PartnerNews
0
0
0
AI is reshaping how we discover drugs and https://t.co/p64DdvtDFe is leading the way. We're proud to welcome them to Illumina Ventures Labs, where they'll use Illumina NGS technology + hyperscaled data to accelerate protein #DrugDiscovery. 🔗 https://t.co/Dg0KZf25YN
#Biotech
0
0
0
Congrats to portfolio company @iambic_ai on raising over $100M to advance AI-driven #DrugDiscovery. This funding will accelerate development of its Enchant and NeuralPLexer platforms and expand its pipeline of innovative therapeutics. https://t.co/dUenuXghqg
#PartnerNews
Pleased to announce Iambic has raised $100M+ in an oversubscribed round to accelerate its AI-discovered therapeutics pipeline & platform. Support from new & existing life sci, tech, growth & sovereign wealth investors underscores strong conviction. More: https://t.co/8f2GWrpgvh
0
0
1
Portfolio company Hepta launched from stealth with $6.7M to redefine liver disease #diagnostics with #LiquidBiopsy. Its #AI platform analyzes DNA fragments, detecting fewer false positives than standard tests. 🎉 Congrats, Hepta team! https://t.co/VByvibbrGH
#PartnerNews
businesswire.com
Hepta, a biotechnology company using transformer-based AI to read the cell-free DNA (cfDNA) epigenome and detect organ-specific signals of chronic disease, t...
0
0
0
Nov. 12-13, @Tech_Networks is hosting The Spatial Biology Revolution 2025. Joshua Weinstein, PhD, Advisor to portfolio company Cubase Bio, will present on scalable 3D spatial #genomics on Nov. 12 at 9:55 am PT. Register for the free, virtual event: https://t.co/zVUtATxPOW
0
0
1
Illumina Ventures Principal Charles Lin, PhD, and portfolio company Iambic Therapeutics CEO and Co-Founder Tom Miller, PhD, will attend the 21st Annual Industry/Academia Precision Oncology & RadMed Symposium on 11/5 in La Jolla, CA. https://t.co/tSmPX25Qc1
#DrugDiscovery
0
0
0
Thank you to @HLTHEVENT for giving Partner Mara Aspinall the opportunity to lead an important panel on how #diagnostics are expanding and improving to deliver meaningful insights to patients with actionable implications. #HLTHUSA
0
1
1
Partner Mara Aspinall will moderate a @HLTHEVENT panel on 10/21, 11:45 am-12:25 pm on the Holos Stage, discussing the move from traditional #diagnostics to consumer-focused, accessible testing and predictive insights. Details: https://t.co/U2qY66bXXi
#hlthusa
0
0
0
On October 15, Partner Mara Aspinall will speak at the @ASU National Diagnostics Summit 2025. The event will explore the future of #diagnostics with a focus on #AI in labs and test manufacturing. Details: https://t.co/tioB14ap3x
0
0
1
On 10/16, Partner Mara Aspinall and Global Head of Illumina Ventures Labs Marc Martin-Casas will speak at the @AZAdvances Health Innovation Summit on the “Investing in Innovation” panel. Details: https://t.co/AUjZzqLJeP
0
0
1
🎉 Congrats to portfolio company @arbortx on their new strategic partnership with @ChiesiGRD to advance gene editing therapies for rare diseases and redefine care for patients with PH1 and other rare genetic conditions. Details: https://t.co/oUwvlca4o6
#PartnerNews #GeneTherapy
arbor.bio
PARMA, ITALY & CAMBRIDGE, MA, USA – October 6, 2025 – Chiesi Group, an international research-oriented biopharmaceutical company, together with Arbor Biotechnologies, Inc., a next-generation biotec...
Thrilled to announce our strategic collaboration with @ChiesiGRD on the development of ABO-101 for #PH1 and additional #raredisease targets. Together, we are committed to bringing hope to patients & their families through meaningful innovation. Learn more: https://t.co/Y2ru2yzf7H
0
0
0
In our latest CEO Spotlight, @ArimaGenomics CEO Tom Willis, PhD, unpacks Arima’s fascinating journey and how its tech goes beyond traditional sequencing, preserving the original 3D structure of DNA to unlock hidden cancer signals. 👉 Full conversation: https://t.co/183MfLZJBs
0
0
1
Partner Mara Aspinall will speak at @ConcertGenetics’ Precision Health Information Network Summit 2025, 10/8-10, a multi-stakeholder gathering focused on the data, digital infrastructure and economic challenges facing #PrecisionMedicine. https://t.co/PBEFAUFBu3
precisionnetworksummit.com
0
0
1
🎉Congrats to portfolio company @PredictaBiosci on the close of a $23.4 million #SeriesA and appointment of CEO Brian McKernan. The funding will support development of #diagnostics for blood cancers and autoimmune diseases. 📢 Announcement: https://t.co/x9IlXlaEnz
#PartnerNews
0
1
2
Thrilled to share Partner Mara Aspinall will moderate a @HLTHEVENT panel on 10/21 in Las Vegas, discussing the move from traditional #diagnostics to consumer-focused, accessible testing and predictive insights. Details: https://t.co/U2qY66bq7K
#HLTHUSA
0
0
0
Partner Ron Mazumder, PhD, will attend the Oncology, Venturing, Innovation & Partnering Summit 9/29-30 in Boston with thought leaders and decision-makers exploring #oncology #innovation, #funding strategies & strategic partnerships. Details: https://t.co/3sFNyweSeF
#OncologyVIP
0
0
2
Partner Ron Mazumder, PhD, will attend the JHU Innovation Summit '25 on 9/18 in Baltimore. 11 @JohnsHopkins research lab #startups will present and @DELFIDiagnostic Founder & Board Director Victor Velculescu, MD, PhD, will give a fireside chat. Details: https://t.co/rEFxPaKyWP
0
0
0